Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus–induced type 2 responses and immunopathology - 04/08/18
Supported by grants R01 AI 124456, U19 AI 095227, R01 AI 111820, and 2I01BX000624 (to R.S.P.); T32 GM07347 (to the Vanderbilt MSTP); and F30 AI118376 (to M.H.B.). The VUMC Flow Cytometry Shared Resource is supported by the Vanderbilt Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease Research Center (DK058404). The PheWAS study was supported by the National Center for Research Resources, grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
Disclosure of potential conflict of interest: J. D. Chappell has received grants from the National Institutes of Health (NIH) and the Department of Veterans Affairs. T. V. Hartert has received a grant from the NIH. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 2
P. 683 - août 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?